Elutia Inc. reported its financial results for the third quarter ended September 30, 2026, and provided updates on its product pipeline. The company announced that it intends to submit NXT-41x, its leading drug delivery program, to the FDA in the fourth quarter of 2026. This plan
Elutia Inc. Reports Third Quarter 2026 Results and Plans NXT-41x FDA Submission
Elutia Inc. reported its financial results for the third quarter ended September 30, 2026, and provided updates on its p...
By Dhallo News · November 6, 2026 at 2:59 PM IST
Have feedback on this article?Report error or suggestion
